C
온코크로스
382150KOSDAQ자연과학 및 공학 연구개발업46.0 / 100
Reference Date: 2026-04-13
Financial Score11.5 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Rose 10.7% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
OncoCross is a company that enhances drug development efficiency through its AI platform 'RAPTOR AI', which matches optimal diseases with therapies based on gene expression and protein data. It is also developing 'RAPTOR AI v2.0' to analyze next-generation modalities like ADC and TPD, and expanding its B2B market through the 'Neo Omics' service.
Number of Employees
40people
Average Salary
75.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
7.25Industry Average 3.821.0Point
1.9x industry avg (risky)
ROE
-52.79Industry Average -32.113.5Point
1.6x industry avg (good)
Debt Ratio
73.51Industry Average 7.520.0Point
9.8x industry avg (risky)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲503.0% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼14.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -42.6% (declining, 3yr)
Detailed News Sentiment
6 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50
- Neutral
Detailed Momentum
52-week position1.0Point
Near 52w low (18%, downtrend)
Current 7,950Won52-week high 15,59052-week low 6,210
1-month return5.0Point
1m +10.72% (rising)
Volume trend6.0Point
Volume surge
Detailed Disclosure
10 totalPositive 0Neutral 10Negative 0
- Neutral[기재정정]주식매수선택권부여에관한신고2026-04-09
- Neutral주식매수선택권부여에관한신고2026-04-09
- Neutral주식등의대량보유상황보고서(일반)2026-04-07
- Neutral[기재정정]주식매수선택권부여에관한신고2026-04-01
- Neutral주식매수선택권부여에관한신고2026-03-27